Structural differences between blood-platelet tubulin and other mammalian tubulins.

M. Little,R. Quinlan,C. Röhricht,J. Díez

DOI: https://doi.org/10.1016/0167-4838(87)90213-5

1987-11-05

Biochimica et Biophysica Acta

Abstract:

What problem does this paper attempt to address?

Protective Effects of Auricularia Auriculajudae Polysaccharide on Vascular of Streptozotocin Induced Diabetic Rats

Linlin Wang,Wangmin Situ,Jiaqian Fei,Xiaoming Zhang,Tingmei Ye,Yueliang Shen,Yingying Chen

DOI: https://doi.org/10.1096/fasebj.23.1_supplement.578.12

2009-01-01

Abstract:AimTo investigate the direct vascular effects of auricularia auriculajudae polysaccharide (AAP) and the underlying mechanisms on the thoracic aorta of streptozotocin(STZ) induced diabetic SD rats.MethodsThe thoracic aortic rings with endothelium from STZ induced diabetic rats were mounted in an organ bath. Isometric contraction of aortic rings was measured. On the other hand, isolated aortic rings from normal control SD rats were conducted with immuno‐histochemical analysis for induced nitric oxide synthase (iNOS) expression after they were pre‐incubated with APP (10 μg/ml) for 0~50 minutes.Results(1) Cumulative administration of AAP (2‐20 μg/ml) did not affect the vasomotion of aortic rings of diabetic rats in basal tension. (2) After incubation with APP (10 μg/ml) for 30 minutes, aorta rings with endothelium were pre‐contracted with PE (10−6 M) and then acetylcholine (Ach) were added. The vascular relaxation response to Ach was significantly impaired in diabetic group, which was completely reversed by APP treatment. (2) The expression levelof iNOS in aortic rings was markedly increased after incubated with APP. iNOS expression had a peak level at time point of 10 minutes.ConclusionAPP could restore the vasorelexation dysfunction in diabetic rat aortic rings, in which the activation of NO pathway may probably be involved.
Pentamethylquercetin Attenuates Angiotensin II-induced Abdominal Aortic Aneurysm Formation by Blocking Nuclear Translocation of C/EBPβ at Lys253

Hanlin Wu,Jing Wang,Yuxin Bu,Jia Li,Yiming Li,Quanmin Jing,Xiaozeng Wang,Chenghui Yan,Dan Liu,Yaling Han

DOI: https://doi.org/10.1016/j.bbadis.2024.167224

2024-01-01

Biochimica et Biophysica Acta - Molecular Basis of Disease

Abstract:Background: Pentamethylquercetin (PMQ) is a natural polymethyl flavonoid that possesses anti-apoptotic and other biological properties. Abdominal aortic aneurysm (AAA), a fatal vascular disease with a high risk of rupture, is associated with phenotypic switching and apoptosis of medial vascular smooth muscle cells (VSMCs). This study aimed to investigate the protective effects of PMQ on the development of AAA and the underlying mechanism. Methods: ApoE-/- mice were continuously infused with angiotensin II (Ang II) for 4 weeks to develop the AAA model. Intragastric administration of PMQ was initiated 5 days before Ang II infusion and continued for 4 weeks. In vitro, VSMCs were cultured and pretreated with PMQ, stimulated with Ang II. Real-time PCR, western blotting, and immunofluorescence staining were used to examine the roles and mechanisms of PMQ on the phenotypic switching and apoptosis of VSMCs. Results: PMQ dose-dependently reduced the incidence of Ang II-induced AAA, aneurysm diameter enlargement, elastin degradation, VSMCs phenotypic switching and apoptosis. Furthermore, PMQ also inhibited phenotypic switching and apoptosis in Ang II-stimulated VSMCs. PMQ exerted protective effects by regulating the C/EBP beta/ PTEN/AKT/GSK-3 beta axis. AAV-mediated overexpression of PTEN reduced the therapeutic effects of PMQ in the AAA model mice, suggesting that the effects of PMQ on Ang II-mediated AAA formation were related to the PTEN/AKT/GSK-3 beta axis. PMQ inhibited VSMCs phenotypic switching and apoptosis by bounding to C/EBP beta at Lys253 with hydrogen bond to regulate C/EBP beta nuclear translocation and PTEN/AKT/GSK-3 beta axis, thereby inhibiting Ang II-induced AAA formation. Conclusions: Pentamethylquercetin inhibits angiotensin II-induced abdominal aortic aneurysm formation by bounding to C/EBP beta at Lys253. Therefore, PMQ prevents the formation of AAA and reduces the incidence of AAA.
Activation AMPK in Hypothalamic Paraventricular Nucleus Improves Renovascular Hypertension Through ERK1/2-NF-κB Pathway

Li-Yan Fu,Yu Yang,Rui-Juan Li,Abdoulaye Issotina Zibrila,Hua Tian,Xiu-Yue Jia,Jin-An Qiao,Jin-Min Wu,Jie Qi,Xiao-Jing Yu,Yu-Ming Kang

DOI: https://doi.org/10.1007/s12012-024-09888-9

Abstract:Hypertension is a globally prevalent disease, but the pathogenesis remains largely unclear. AMP-activated protein kinase (AMPK) is a nutrition-sensitive signal of cellular energy metabolism, which has a certain influence on the development of hypertension. Previously, we found a down-regulation of the phosphorylated (p-) form of AMPK, and the up-regulation of the angiotensin II type 1 receptor (AT1-R) and that of p-ERK1/2 in the hypothalamic paraventricular nucleus (PVN) of hypertensive rats. However, the exact mechanism underlying the relationship between AMPK and AT1-R in the PVN during hypertension remains unclear. Thus, we hypothesized that AMPK modulates AT1-R through the ERK1/2-NF-κB pathway in the PVN, thereby inhibiting sympathetic nerve activity and improving hypertension. To examine this hypothesis, we employed a renovascular hypertensive animal model developed via two-kidney, one-clip (2K1C) and sham-operated (SHAM). Artificial cerebrospinal fluid (aCSF), used as vehicle, or 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR, an AMPK activator, 60 μg/day) was microinjected bilaterally in the PVN of these rats for 4 weeks. In 2K1C rats, there an increase in systolic blood pressure (SBP) and circulating norepinephrine (NE). Also, the hypertensive rats had lowered expression of p-AMPK and p-AMPK/AMPK, elevated expression of p-ERK1/2, p-ERK1/2/ERK1/2 and AT1-R, increased NF-κB p65 activity in the PVN compared with the levels of these biomarkers in SHAM rats. Four weeks of bilateral PVN injection of AMPK activator AICAR, attenuated the NE level and SBP, increased the expression of p-AMPK and p-AMPK/AMPK, lessened the NF-κB p65 activity, decreased the expression of p-ERK1/2, p-ERK1/2/ERK1/2 and AT1-R in the PVN of 2K1C rats. Data from this study imply that the activation of AMPK within the PVN suppressed AT1-R expression through inhibiting the ERK1/2-NF-κB pathway, decreased the activity of the sympathetic nervous system, improved hypertension.
Quercetin Improves Vascular Endothelial Function Through Promotion of Autophagy in Hypertensive Rats

Xuemei Lin,Tuo Han,Yajie Fan,Songdi Wu,Fang Wang,Congxia Wang

DOI: https://doi.org/10.1016/j.lfs.2020.118106

IF: 6.78

2020-01-01

Life Sciences

Abstract:AimsEndothelial dysfunction is a hallmark of hypertension. Herein, we assessed the effect of quercetin, a common dietary antioxidant, on endothelial function of spontaneously hypertensive rats (SHRs), and investigated the underlying molecular mechanisms.Main methodsThe Wistar-Kyoto (WKY) and SHR rats were administered vehicle (1% w/v methyl cellulose) or quercetin (10 mg/kg body weight) by oral gavage once a day for 6 weeks. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured with a tail-cuff system. Functional of rat mesenteric arterioles was assessed by the temperature-controlled myograph. A dose-response curve was generated by the cumulative addition of acetylcholine (ACh) or sodium nitroprusside (SNP). NO production in the culture medium was assessed by measuring the concentration of nitrite, a stable metabolite of NO, using a modified Griess reagent.Key findingsQuercetin improved endothelial function and decreased blood pressure in SHRs. Endothelial autophagy, an important cellular homeostatic process, was increased in the early phase of treatment, and decreased in the late phase of treatment. Quercetin promoted autophagy in cultured endothelial cells under both normal and oxidative stress conditions. Pharmacological inhibition of autophagy aggravated endothelial dysfunction in quercetin-treated endothelial cells under oxidative stress, and attenuated the antihypertensive and endothelial protective effects of quercetin in SHRs.SignificanceQuercetin protects endothelial function in hypertensive rats through promotion of autophagy. Thus, autophagy could serve as a potential therapeutic target for hypertension.
Vascular protein disulfide isomerase A1 mediates endothelial dysfunction induced by angiotensin II in mice

Agnieszka Kij,Anna Bar,Izabela Czyzynska‐Cichon,Kamil Przyborowski,Bartosz Proniewski,Lukasz Mateuszuk,Zuzanna Kurylowicz,Agnieszka Jasztal,Elzbieta Buczek,Anna Kurpinska,Joanna Suraj‐Prazmowska,Brygida Marczyk,Karolina Matyjaszczyk‐Gwarda,Andreas Daiber,Matthias Oelze,Maria Walczak,Stefan Chlopicki

DOI: https://doi.org/10.1111/apha.14116

IF: 7.523

2024-02-25

Acta Physiologica

Abstract:Aim Protein disulfide isomerases (PDIs) are involved in platelet aggregation and intravascular thrombosis, but their role in regulating endothelial function is unclear. Here, we characterized the involvement of vascular PDIA1 in angiotensin II (Ang II)‐induced endothelial dysfunction in mice. Methods Endothelial dysfunction was induced in C57BL/6JCmd male mice via Ang II subcutaneous infusion, and PDIA1 was inhibited with bepristat. Endothelial function was assessed in vivo with magnetic resonance imaging and ex vivo with a myography, while arterial stiffness was measured as pulse wave velocity. Nitric oxide (NO) bioavailability was measured in the aorta (spin‐trapping electron paramagnetic resonance) and plasma (NO2− and NO3− levels). Oxidative stress, eNOS uncoupling (DHE‐based aorta staining), and thrombin activity (thrombin–antithrombin complex; calibrated automated thrombography) were evaluated. Results The inhibition of PDIA1 by bepristat in Ang II‐treated mice prevented the impairment of NO‐dependent vasodilation in the aorta as evidenced by the response to acetylcholine in vivo, increased systemic NO bioavailability and the aortic NO production, and decreased vascular stiffness. Bepristat's effect on NO‐dependent function was recapitulated ex vivo in Ang II‐induced endothelial dysfunction in isolated aorta. Furthermore, bepristat diminished the Ang II‐induced eNOS uncoupling and overproduction of ROS without affecting thrombin activity. Conclusion In Ang II‐treated mice, the inhibition of PDIA1 normalized the NO‐ROS balance, prevented endothelial eNOS uncoupling, and, thereby, improved vascular function. These results indicate the importance of vascular PDIA1 in regulating endothelial function, but further studies are needed to elucidate the details of the mechanisms involved.

physiology
The hydroxamic acid derivative YPX-C-05 alleviates hypertension and vascular dysfunction through the PI3K/Akt/eNOS pathway

Pan-Pan Pang,Hao Sun,Pei-Xia Yu,Wei-Min Yang,Yong-Tang Zheng,Xun Li,Chang-Bo Zheng,Pei-xia Yu,Wei-min Yang

DOI: https://doi.org/10.1016/j.vph.2023.107251

IF: 5.738

2023-12-05

Vascular Pharmacology

Abstract:Background Hypertension is a prevalent cardiovascular disease characterized by elevated blood pressure and increased vascular resistance. HDAC inhibitors have emerged as potential therapeutic agents due to their ability to modulate gene expression and cellular processes. YPX-C-05, a novel hydroxamic acid-based HDAC inhibitor, shows promise in its vasodilatory effects and potential targets for hypertension treatment. In this study, we aimed to elucidate the mechanisms underlying YPX-C-05's vasodilatory effects and explore its therapeutic potential in hypertension. Methods To determine the ex vivo vasodilatory effects of YPX-C-05, isolated aortic rings precontracted with phenylephrine were used. We assessed YPX-C-05's inhibitory effects on HDACs and its impact on histone H4 deacetylation levels in endothelial cells. Network pharmacology analysis was employed to predict putative targets of YPX-C-05 for hypertension treatment. To investigate the involvement of the PI3K/Akt/eNOS pathway, we employed enzyme-linked immunosorbent assay and to assess the levels of NO, ET-1, BH2, and BH4 in human umbilical vein endothelial cells. And we also analyzed the mRNA expression of eNOS and ET-1. Furthermore, Western blotting was conducted to quantify the phosphorylated and total Akt and eNOS levels in human umbilical vein endothelial cell lysates following treatment with YPX-C-05. In order to elucidate the vasodilatory mechanism of YPX-C-05, we employed pharmacological inhibitors for evaluation purposes. Furthermore, we evaluated the chronic antihypertensive effects of YPX-C-05 on N-omega-nitro-L-arginine-induced hypertensive mice in an in vivo model. Vascular remodeling was assessed through histological analysis. Results Our findings demonstrated that YPX-C-05 exerts significant vasodilatory effects in isolated aortic rings precontracted with phenylephrine. Furthermore, YPX-C-05 exhibited inhibitory effects on HDACs and increased histone H4 acetylation in endothelial cells. Network pharmacology analysis predicted YPX-C-05 might activate endothelial eNOS via PI3K/Akt signaling pathway. Inhibition of the PI3K/Akt/eNOS pathway attenuated the vasodilatory effects of YPX-C-05, as evidenced by reduced levels of phosphorylated Akt and eNOS in human umbilical vein endothelial cell lysates. The chronic administration of YPX-C-05 in N-omega-nitro-L-arginine-induced hypertensive mice resulted in significant antihypertensive effects. Histological analysis demonstrated a reduction in vascular remodeling, further supporting the therapeutic potential of YPX-C-05 in hypertension. Conclusion This study demonstrates for the first time that the novel hydroxamic acid-based HDAC inhibitor YPX-C-05 produces significant antihypertensive and vasodilatory effects through the PI3K/Akt/eNOS pathway. Our findings support the developing prospect of YPX-C-05 as a novel antihypertensive drug.

pharmacology & pharmacy
Mitochondrial K ATP channel-mediated autophagy contributes to angiotensin II-induced vascular dysfunction in mice

Xue-Min Yin,Yi-Yi Song,Wen-Yi Jiang,Hao-Tian Zhang,Jing-Wei Chen,Koji Murao,Meng-Xiao Han,Wan-Ping Sun,Guo-Xing Zhang

DOI: https://doi.org/10.1016/j.numecd.2024.01.019

IF: 4.666

2024-01-29

Nutrition Metabolism and Cardiovascular Diseases

Abstract:Background and Aim The present study aimed to investigate whether the mitochondrial K ATP channel contributes to angiotensin II (Ang II)-induced vascular dysfunction, the development of hypertension, and atherosclerosis. Methods and Results ApoE (-/-) mice fed a high-fat diet were chronically infused with Ang II for eight weeks and concomitantly treated with losartan (ARB), apocynin, or 5-hydroxy decanoate (5-HD), or 3-methyladenine (3-MA). Systolic blood pressure was measured, and pathological changes of aortic or liver tissue were observed. Nitric oxide (NO), superoxide dismutase 2 (SOD2) levels and vasorelaxation rate were measured, and protein and mRNA expressions were examined by western blot and RT-PCR. Ang II-induced development of hypertension was suppressed not only by ARB, and apocynin but also by 5-HD or 3-MA. Ang II infusion decreased aortic NO production and relaxation, as well as SOD2 activity in liver, which were improved by all treatments. In addition, Ang II-induced activation of autophagy was suppressed by 5-HD in aortic tissue, furthermore, Ang II increases the atherosclerotic index in plasma and exacerbates the development of atherosclerosis by increases of fat deposition in the aorta and liver. Lipid metabolism-related mRNA expressions (LXR-α, LDLR, SRBI, Acca, and FASN) were changed by Ang II. Similarly, not only ARB, and apocynin, but also 5-HD and 3-MA suppressed Ang II-induced these changes. Conclusions Our present findings evidence that mitochondrial K ATP channel-mediated autophagy contributes to Ang II-induced vascular dysfunction, development of hypertension, and atherosclerosis.

cardiac & cardiovascular systems,endocrinology & metabolism,nutrition & dietetics
Angiotensin II Decreases Endothelial Nitric Oxide Synthase Phosphorylation via AT1R Nox/ROS/PP2A Pathway

Jing Ding,Min Yu,Juncai Jiang,Yanbei Luo,Qian Zhang,Shengnan Wang,Fei Yang,Alei Wang,Lingxiao Wang,Mei Zhuang,Shan Wu,Qifang Zhang,Yong Xia,Deqin Lu

DOI: https://doi.org/10.3389/fphys.2020.566410

IF: 4

2020-09-30

Frontiers in Physiology

Abstract:Increasing evidences suggest that angiotensin (Ang) II participates in the pathogenesis of endothelial dysfunction (ED) through multiple signaling pathways, including angiotensin type 1 receptor (AT1R) mediated NADPH oxidase (Nox)/reactive oxygen species (ROS) signal transduction. However, the detailed mechanism is not completely understood. In this study, we reported that AngII/AT1R-mediated activated protein phosphatase 2A (PP2A) downregulated endothelial nitric oxide synthase (eNOS) phosphorylation via Nox/ROS pathway. AngII treatment reduced the levels of phosphorylation of eNOS Ser1177 and nitric oxide (NO) content along with phosphorylation of PP2Ac (PP2A catalytic subunit) Tyr307, meanwhile increased the PP2A activity and ROS production in human umbilical vein endothelial cells (HUVECs). These changes could be impeded by AT1R antagonist candesartan (CAN). The pretreatment of 10−8 M PP2A inhibitor okadaic acid (OA) reversed the levels of eNOS Ser1177 and NO content. Similar effects of AngII on PP2A and eNOS were also observed in the mesenteric arteries of Sprague-Dawley rats subjected to AngII infusion via osmotic minipumps for 2 weeks. We found that the PP2A activity was increased, but the levels of PP2Ac Tyr307 and eNOS Ser1177 as well as NO content were decreased in the mesenteric arteries. The pretreatments of antioxidant N-acetylcysteine (NAC) and apocynin (APO) abolished the drop of the levels of PP2Ac Tyr307 and eNOS Ser1177 induced by AngII in HUVECs. The knockdown of p22phox by small interfering RNA (siRNA) gave rise to decrement of ROS production and increment of the levels of PP2Ac Tyr307 and eNOS Ser1177. These results indicated that AngII/AT1R pathway activated PP2A by downregulating its catalytic subunit Tyr307 phosphorylation, which relies on the Nox activation and ROS production. In summary, our findings indicate that AngII downregulates PP2A catalytic subunit Tyr307 phosphorylation to activate PP2A via AT1R-mediated Nox/ROS signaling pathway. The activated PP2A further decreases levels of eNOS Ser1177 phosphorylation and NO content leading to endothelial dysfunction.

physiology
Vascular adenosine monophosphate-activated protein kinase: Enhancer, brake or both?

Hui Chen,Paul Michel Vanhoutte,Susan Wai Sum Leung

DOI: https://doi.org/10.1111/bcpt.13357

Abstract:Adenosine monophosphate-activated protein kinase (AMPK), expressed/present ubiquitously in the body, contributes to metabolic regulation. In the vasculature, activation of AMPK is associated with several beneficial biological effects including enhancement of vasodilatation, reduction of oxidative stress and inhibition of inflammatory reactions. The vascular protective effects of certain anti-diabetic (metformin and sitagliptin) or lipid-lowering (simvastatin and fenofibrate) therapeutic agents, of active components of Chinese medicinal herbs (resveratrol and berberine) and of pharmacological agents (AICAR, A769662 and PT1) have been attributed to the activation of AMPK (in endothelial cells, vascular smooth muscle cells and/or perivascular adipocytes), independently of changes in the metabolic profile (eg glucose tolerance and/or plasma lipoprotein levels), leading to improved endothelium-derived nitric oxide-mediated vasodilatation and attenuated endothelium-derived cyclooxygenase-dependent vasoconstriction. By contrast, endothelial AMPK activation with pharmacological agents or by genetic modification is associated with reduced endothelium-dependent relaxations in small blood vessels and elevated systolic blood pressure. Indeed, AMPK activators inhibit endothelium-dependent hyperpolarization (EDH)-type relaxations in superior mesenteric arteries, partly by inhibiting endothelial calcium-activated potassium channel signalling. Therefore, AMPK activation is not necessarily beneficial in terms of endothelial function. The contribution of endothelial AMPK in the regulation of vascular tone, in particular in the microvasculature where EDH plays a more important role, remains to be characterized.
AMPK attenuates ventricular remodeling and dysfunction following aortic banding in mice via the Sirt3/Oxidative stress pathway

Yili Chen,Cong Chen,Bin Dong,Fuwei Xing,Huiling Huang,Fengjuan Yao,Yuedong Ma,Jiangui He,Yugang Dong

DOI: https://doi.org/10.1016/j.ejphar.2017.08.042

IF: 5.195

2017-11-01

European Journal of Pharmacology

Abstract:Although recent findings have suggested that AMP-activated protein kinase (AMPK) exerts inhibitory effects on cardiac remodeling secondary to hypertension, the mechanism and optimal duration of treatment remain unknown. Mice with descending aortic banding (AB) or subjected to sham operation received subcutaneous injection of either AICAR (0.5mgg-1day-1) or vehicle over 4 week periods. At the end of 4 week treatment, left ventricular (LV) remodeling and function were evaluated with histological analysis and echocardiography. Collagen deposition within the LV myocardium was detected with Masson's trichrome staining. Collagen I, Collagen III, Smad 2, Smad 3, NOX2, NOX4 and Sirt3 (an important antioxidant factor) within the LV tissue were also evaluated. Compared with the sham group, the vehicle-treated AB group exhibited significant elevations in cardiac remodeling and heart failure, characterized by an increase in LV weight relative to body weight, an increase in the area of collagen deposition, an increase in LV end-diastolic diameter, an increase in mitral E inflow velocity to mitral A inflow velocity and increases in the gene expressions of the fibrosis markers Collagen I, III and Smad 2, 3 mRNA and decreases in EF and fractional shortening. AMPK attenuate the cardiac remodeling parameters and improve cardiac function. Moreover, the expressions of NOX2, NOX4 were significantly elevated in vehicle-treated AB group. AMPK was able to significantly inhibit NOX2, NOX4 expression, while activate Sirt3 expression. AMPK significantly attenuated hypertension-induced Ventricular remodeling and dysfunction, which may be mediated by the Sirt3/Oxidative stress signaling pathway.

pharmacology & pharmacy
Paeonol improves renal and vascular angiotensin II type 1 receptor function via inhibiting oxidative stress in spontaneously hypertensive rats

Tingchun Wu,Yuhua Zheng,Qianqian Huang,Shui Tian

DOI: https://doi.org/10.1080/10641963.2023.2182884

2023-03-02

Clinical and Experimental Hypertension

Abstract:Oxidative stress has been shown to play a critical role in the pathogenesis of hypertension. Paeonol, a major phenolic component extracted from Moutan Cortex, exerts a beneficial effect in preventing cardiovascular disease via reducing oxidative stress. The present study investigated the protective mechanism of paeonol against high blood pressure in spontaneous hypertension rats (SHRs). Wistar-Kyoto (WKY) rats and SHRs received vehicle or peaonol in the drinking water for 5 weeks. Blood pressure was measured by tail-cuff plethysmography and oxidative stress in kidney and vascular tissue was examined by enzyme-linked immunosorbed assay. The functions of angiotensin II type 1 receptors (AT 1 R) in the kidney and mesenteric artery were measured by natriuresis and vasoconstrictor response, respectively. Compared with vehicle-treated WKY rats, vehicle-treated SHRs exhibited higher blood pressure, increased oxidative stress, accompanied by exaggerated diuretic and natriuretic responses to candesartan (AT 1 receptor antagonist) and vasoconstrictor responses to angiotensin II (Ang II). Moreover, SHRs had higher ACE and AT 1 R in the kidney and mesenteric artery, and higher Ang II and lower renin levels. Interestingly, paeonol treatment reduced the candesartan-induced increase in diuresis and natriuresis and vasoconstrictor responses to Ang II, and lowered blood pressure in SHRs, accompanied by reducing AT 1 R protein expression in the kidney and mesenteric artery of SHR, and Ang II levels in plasma and increasing renin levels in renal cortex. In addition, these changes were associated with reducing oxidative stress. The present study suggests that paeonol improves renal and vascular AT 1 R functions by inhibition of oxidative stress, thus lowering blood pressure in SHRs.

pharmacology & pharmacy,peripheral vascular disease
Short-chain Acyl-Coa Dehydrogenase is a Potential Target for the Treatment of Vascular Remodelling

Xiaoyi Zhong,Zhonghong Li,Qingping Xu,Huan Peng,Yongshao Su,Kang Le,Zhaohui Shu,Yingqin Liao,Zhichao Ma,Xuediao Pan,Suowen Xu,Sigui Zhou

DOI: https://doi.org/10.1097/hjh.0000000000003399

IF: 4.9

2023-01-01

Journal of Hypertension

Abstract:Objectives: Short-chain acyl-CoA dehydrogenase (SCAD), a key enzyme in the fatty acid oxidation process, is not only involved in ATP synthesis but also regulates the production of mitochondrial reactive oxygen species (ROS) and nitric oxide synthesis. The purpose of this study was to investigate the possible role of SCAD in hypertension-associated vascular remodelling. Methods: In-vivo experiments were performed on spontaneously hypertensive rats (SHRs, ages of 4 weeks to 20 months) and SCAD knockout mice. The aorta sections of hypertensive patients were used for measurement of SCAD expression. In-vitro experiments with t-butylhydroperoxide (tBHP), SCAD siRNA, adenovirus-SCAD (MOI 90) or shear stress (4, 15 dynes/cm2) were performed using human umbilical vein endothelial cells (HUVECs). Results: Compared with age-matched Wistar rats, aortic SCAD expression decreased gradually in SHRs with age. In addition, aerobic exercise training for 8 weeks could significantly increase SCAD expression and enzyme activity in the aortas of SHRs while decreasing vascular remodelling in SHRs. SCAD knockout mice also exhibited aggravated vascular remodelling and cardiovascular dysfunction. Likewise, SCAD expression was also decreased in tBHP-induced endothelial cell apoptosis models and the aortas of hypertensive patients. SCAD siRNA caused HUVEC apoptosis in vitro, whereas adenovirus-mediated SCAD overexpression (Ad-SCAD) protected against HUVEC apoptosis. Furthermore, SCAD expression was decreased in HUVECs exposed to low shear stress (4 dynes/cm2) and increased in HUVECs exposed to 15 dynes/cm2 compared with those under static conditions. Conclusion: SCAD is a negative regulator of vascular remodelling and may represent a novel therapeutic target for vascular remodelling.
Adenosine Kinase Inhibition Enhances Microvascular Dilator Function and Improves Left Ventricle Diastolic Dysfunction

Alec Davila,Yanna Tian,Istvan Czikora,Amanda S. Weissman,Nicholas Weinand,Guangkuo Dong,Jiean Xu,Jie Li,Huabo Su,Gaston Kapuku,Yuqing Huo,Zsolt Bagi

DOI: https://doi.org/10.1111/micc.12624

2020-01-01

Microcirculation

Abstract:Objective Inhibition of adenosine kinase (ADK), via augmenting endogenous adenosine levels exerts cardiovascular protection. We tested the hypothesis that ADK inhibition improves microvascular dilator and left ventricle (LV) contractile function under metabolic or hemodynamic stress. Methods and Results In Obese diabetic Zucker fatty/spontaneously hypertensive heart failure F1 hybrid rats, treatment with the selective ADK inhibitor, ABT-702 (1.5 mg/kg, intraperitoneal injections for 8-week) restored acetylcholine-, sodium nitroprusside-, and adenosine-induced dilations in isolated coronary arterioles, an effect that was accompanied by normalized end-diastolic pressure (in mm Hg, Lean: 3.4 +/- 0.6, Obese: 17.6 +/- 4.2, Obese + ABT: 6.6 +/- 1.4) and LV relaxation constant, Tau (in ms, Lean: 6.9 +/- 1.5, Obese: 13.9 +/- 1.7, Obese + ABT: 6.0 +/- 1.1). Mice with vascular endothelium selective ADK deletion (ADK(VEC)KO) exhibited an enhanced dilation to acetylcholine in isolated gracilis muscle (lgEC(50) WT: -8.2 +/- 0.1, ADK(VEC)KO: -8.8 +/- 0.1, P < .05) and mesenteric arterioles (lgEC(50) WT: -7.4 +/- 0.2, ADK(VEC)KO: -8.1 +/- 1.2, P < .05) when compared to wild-type (WT) mice, whereas relaxation of the femoral artery and aorta (lgEC(50) WT: -7.03 +/- 0.6, ADK(VEC)KO: -7.05 +/- 0.8) was similar in the two groups. Wild-type mice progressively developed LV systolic and diastolic dysfunction when they underwent transverse aortic constriction surgery, whereas ADK(VEC)-KO mice displayed a lesser degree in decline of LV function. Conclusions Our results indicate that ADK inhibition selectively enhances microvascular vasodilator function, whereby it improves LV perfusion and LV contractile function under metabolic and hemodynamic stress.
Dual-Functional MN-08 Attenuated Pulmonary Arterial Hypertension Through Vasodilation and Inhibition of Pulmonary Arterial Remodeling

Fangcheng Luo,Liangmiao Wu,Guoqing Xie,FangFang Gao,Zhixiang Zhang,Guangying Chen,Zheng Liu,Ling Zha,Gaoxiao Zhang,Yewei Sun,Zaijun Zhang,Yuqiang Wang

DOI: https://doi.org/10.1161/hypertensionaha.120.15994

IF: 9.8968

2021-03-29

Hypertension

Abstract:Pulmonary arterial hypertension (PAH) is a rare, progressive pulmonary vascular disease with limited therapeutic options. Pulmonary circulation resistance, pulmonary vascular remodeling, and over-activated NMDARs (N-methyl-d-aspartate receptors) play vital roles in the pathogenesis of PAH. In the present study, we aimed to evaluate the efficacy and molecular mechanism of MN-08, a dual-functional memantine nitrate derivative, in experimental animal models of PAH. MN-08 showed a high degree of accumulation in the lungs and dilated pulmonary arterial rings ex vivo by releasing nitric oxide. MN-08 did not lower systemic blood pressure. MN-08 attenuated right ventricular systolic pressure and right ventricular hypertrophy, inhibited pulmonary arterial remodeling, alleviated glutamate-NMDARs dysregulation, and improved survival rates in monocrotaline-induced PAH rats. More importantly, the therapeutic benefit of MN-08 for PAH was greater than that of sildenafil. Moreover, MN-08 can reduce right ventricular systolic pressure in U46619-induced acute PAH rats. Mechanistically, MN-08 suppressed proliferation of pulmonary arterial smooth muscle cells exposed to human platelet-derived growth factor-BB by regulating the cell cycle and expression of NMDAR1, AKT (serine/threonine kinase Akt), and ERK (extracellular signal-regulated kinase) 1/2. In conclusion, our studies demonstrated that MN-08 may be a promising therapeutic agent for PAH.

peripheral vascular disease
Panax Quinquefolium Saponins enhances angiogenesis in rats with diabetes and myocardial infarction

Deng Pan,Lin Xu,Pengfei Chen,Lina Miao,Yi Tian,Dazhuo Shi,Ming Guo

DOI: https://doi.org/10.1016/j.jep.2023.117252

IF: 5.195

2023-10-06

Journal of Ethnopharmacology

Abstract:Ethnopharmacological relevance Xi Yang Shen ( Panax quinquefolium L.) was originally recorded in "Ben Cao Cong Xin" edited by Wu Yiluo during the Qing Dynasty. Panax Quinquefolium Saponins (PQS) is the main component derived from Panax quinquefolium L, and has been wildly used in the treatment of coronary heart disease. Aim of the study This study aims to explore the potential role and underlying mechanisms of PQS in promoting angiogenesis in rats with diabetes and myocardial infarction. Materials and methods Echocardiograms were used to assess cardiac function, while the heart weight to tibia length ratio was calculated to determine cardiac hypertrophy. Hematoxylin and eosin, periodic acid-Schiff and Masson's trichrome staining were used to examine cardiac morphology, myocyte diameter, and myocardial fibrosis . Immunofluorescence staining was employed to evaluate arteriolar density. The transcriptomes were analyzed and bioinformatic analyses were conducted to predict the potential angiogenesis-promoting mechanism of PQS. In addition, RT-PCR and western blotting was utilized to examine the expression of genes and proteins influenced by PQS. Results PQS improved blood glucose, ameliorated cardiac function, reduced cardiac hypertrophy, and enhanced myocardial morphology in diabetic rats with myocardial infarction. PQS was also found to decrease myocyte diameter, curtail myocardial fibrosis, and increase arteriolar density. However, the effects of PQS were abolished following the deletion of protein kinase C δ (PKCδ). Molecular docking predicted strong interactions between the major blood components of PQS and PKCδ. Transcriptomic and bioinformatic analyses indicated that PQS may bolster angiogenesis by activating the VEGF/PI3K-Akt/eNOS pathway in rats with diabetes and myocardial infarction. Finally, the study demonstrated that PQS could inhibit the expression of PKCδ and stimulate the activation of the VEGF/PI3K-Akt/eNOS pathway. Conclusions PQS improves blood glucose, enhances cardiac function, mitigates cardiac damage, and boosts arteriolar density. The angiogenic impact of PQS appears to be, at least partially, due to its modulation of the PKCδ-mediated VEGF/PI3K-Akt/eNOS signaling pathway in rats with diabetes and myocardial infarction.

pharmacology & pharmacy,chemistry, medicinal,integrative & complementary medicine,plant sciences
Astaxanthin Attenuates Hypertensive Vascular Remodeling by Protecting Vascular Smooth Muscle Cells from Oxidative Stress-Induced Mitochondrial Dysfunction

Yuqiong Chen,Su Li,Yuxuan Guo,Hang Yu,Yandong Bao,Xin,Huimin Yang,Xinzhu Ni,Nan Wu,Dalin Jia

DOI: https://doi.org/10.1155/2020/4629189

2020-01-01

Oxidative Medicine and Cellular Longevity

Abstract:Oxidative stress aggravates mitochondrial injuries and accelerates the proliferation of vascular smooth muscle cells (VSMCs), which are important mechanisms contributing to vascular remodeling in hypertension. We put forward the hypothesis that Astaxanthin (ATX), known to possess strong features of antioxidant, could attenuate vascular remodeling by inhibiting VSMC proliferation and improving mitochondrial function. The potential effects of ATX were tested on spontaneously hypertensive rats (SHRs) and cultured VSMCs that injured by angiotensin II (Ang II). The results showed that ATX lowered blood pressure, reduced aortic wall thickness and fibrosis, and decreased the level of reactive oxygen species (ROS) and H2O2 in tunica media. Moreover, ATX decreased the expression of proliferating cell nuclear antigen (PCNA) and ki67 in aortic VSMCs. In vitro, ATX mitigated VSMC proliferation and migration, decreased the level of cellular ROS, and balanced the activities of ROS-related enzymes including NADPH oxidase, xanthine oxidase, and superoxide dismutase (SOD). Besides, ATX mitigated Ca2+ overload, the overproduction of mitochondrial ROS (mtROS), mitochondrial dysfunction, mitochondrial fission, and Drp1 phosphorylation at Ser616. In addition, ATX enhanced mitophagy and mitochondrial biosynthesis by increasing the expression of PINK, parkin, mtDNA, mitochondrial transcription factor A (Tfam), and PGC-1α. The present study indicated that ATX could efficiently treat vascular remodeling through restraining VSMC proliferation and restoring mitochondrial function. Inhibiting mitochondrial fission by decreasing the phosphorylation of Drp1 and stimulating mitochondrial autophagy and biosynthesis via increasing the expression of PINK, parkin, Tfam, and PGC-1α may be part of its underlying mechanisms.
Dipeptidyl peptidase 4 inhibition rescues PKA-eNOS signaling and suppresses aortic hypercontractility in male rats with heart failure

Milene T Fontes,Daniel F Arruda-Junior,Danúbia Silva Dos Santos,João Carlos Ribeiro-Silva,Edinei L Antônio,Paulo F J Tucci,Luciana V Rossoni,Adriana C C Girardi

DOI: https://doi.org/10.1016/j.lfs.2023.121648

2023-06-15

Abstract:Aims: Vascular dysfunction and elevated circulating dipeptidyl peptidase 4 (DPP4) activity are both reported to be involved in the progression of heart failure (HF). While the cardiac benefits of DPP4 inhibitors (DPP4i) have been extensively studied, little is known about the effects of DPP4i on vascular dysfunction in nondiabetic HF. This study tested the hypothesis that vildagliptin (DPP4i) mitigates aortic hyperreactivity in male HF rats. Materials and methods: Male Wistar rats were subjected to left ventricle (LV) radiofrequency ablation to HF induction or sham operation (SO). Six weeks after surgery, radiofrequency-ablated rats who developed HF were treated with vildagliptin (120 mg⸱kg-1⸱day-1) or vehicle for 4 weeks. Thoracic aorta reactivity, dihydroethidium fluorescence, immunoblotting experiments, and enzyme-linked immunosorbent assays were performed. Key findings: DPP4i ameliorated the hypercontractility of HF aortas to the α-adrenoceptor agonist phenylephrine towards SO levels. In HF, the reduced endothelium and nitric oxide (NO) anticontractile effect on phenylephrine response was restored by DPP4i. At the molecular level, this vasoprotective effect of DPP4i was accompanied by (i) reduced oxidative stress and NADPH oxidase 2 (Nox2) expression, (ii) enhanced total endothelial nitric oxide synthase (eNOS) expression and phosphorylation at Ser1177, and (iii) increased PKA activation, which acts upstream of eNOS. Additionally, DPP4i restored the higher serum angiotensin II concentration towards SO. Significance: Our data demonstrate that DPP4i ameliorates aortic hypercontractility, most likely by enhancing NO bioavailability, showing that the DPP4i-induced cardioprotection in male HF may arise from effects not only in the heart but also in conductance arteries.
Selective Phosphodiesterase 1 Inhibitor BTTQ Reduces Blood Pressure in Spontaneously Hypertensive and Dahl Salt Sensitive Rats: Role of Peripheral Vasodilation

Asim B. Dey,Sherif Khedr,James Bean,Leah L. Porras,Tamika D. Meredith,Francis S. Willard,Joseph V. Hass,Xin Zhou,Maia Terashvili,Cynthia D. Jesudason,Kevin M. Ruley,Michael R. Wiley,Mark Kowala,Simon J. Atkinson,Alexander Staruschenko,Mark D. Rekhter

DOI: https://doi.org/10.3389/fphys.2020.543727

IF: 4

2020-09-08

Frontiers in Physiology

Abstract:Regulation of the peripheral vascular resistance via modulating the vessel diameter has been considered as a main determinant of the arterial blood pressure. Phosphodiesterase enzymes (PDE1-11) hydrolyse cyclic nucleotides, which are key players controlling the vessel diameter and, thus, peripheral resistance. Here, we have tested and reported the effects of a novel selective PDE1 inhibitor (BTTQ) on the cardiovascular system. Normal Sprague Dawley, spontaneously hypertensive (SHR), and Dahl salt-sensitive rats were used to test in vivo the efficacy of the compound. Phosphodiesterase radiometric enzyme assay revealed that BTTQ inhibited all three isoforms of PDE1 in nanomolar concentration, while micromolar concentrations were needed to induce effective inhibition for other PDEs. The myography study conducted on mesenteric arteries revealed a potent vasodilatory effect of the drug, which was confirmed in vivo by an increase in the blood flow in the rat ear arteriols reflected by the rise in the temperature. Furthermore, BTTQ proved a high efficacy in lowering the blood pressure about 9, 36, and 24 mmHg in normal Sprague Dawley, SHR and, Dahl salt-sensitive rats, respectively, compared to the vehicle-treated group. Moreover, additional blood pressure lowering of about 22 mmHg could be achieved when BTTQ was administered on top of ACE inhibitor lisinopril, a current standard of care in the treatment of hypertension. Therefore, PDE1 inhibition induced efficient vasodilation that was accompanied by a significant reduction of blood pressure in different hypertensive rat models. Administration of BTTQ was also associated with increased heart rate in both models of hypertension as well as in the normotensive rats. Thus, PDE1 appears to be an attractive therapeutic target for the treatment of resistant hypertension, while tachycardia needs to be addressed by further compound structural optimization.

physiology
Adiponectin Attenuates Angiotensin II-Induced Vascular Smooth Muscle Cell Remodeling through Nitric Oxide and the RhoA/ROCK Pathway

Wared Nour-Eldine,Crystal M. Ghantous,Kazem Zibara,Leila Dib,Hawraa Issaa,Hana A. Itani,Nabil El-Zein,Asad Zeidan

DOI: https://doi.org/10.3389/fphar.2016.00086

IF: 5.6

2016-04-07

Frontiers in Pharmacology

Abstract:INTRODUCTION: Adiponectin (APN), an adipocytokine, exerts protective effects on cardiac remodeling, while angiotensin II (Ang II) induces hypertension and vascular remodeling. The potential protective role of APN on the vasculature during hypertension has not been fully elucidated yet. Here, we evaluate the molecular mechanisms of the protective role of APN in the physiological response of the vascular wall to Ang II.METHODS AND RESULTS: Rat aortic tissues were used to investigate the effect of APN on Ang II-induced vascular remodeling and hypertrophy. We investigated whether nitric oxide (NO), the RhoA/ROCK pathway, actin cytoskeleton remodeling, and reactive oxygen species (ROS) mediate the anti-hypertrophic effect of APN. Ang II-induced protein synthesis was attenuated by pre-treatment with APN, NO donor S-nitroso-N-acetylpenicillamine (SNAP), or cGMP. The hypertrophic response to Ang II was associated with a significant increase in RhoA activation and vascular force production, which were prevented by APN and SNAP. NO was also associated with inhibition of Ang II-induced phosphorylation of cofilin. In addition, immunohistochemistry revealed that 24 h Ang II treatment increased the F- to G-actin ratio, an effect that was inhibited by SNAP. Ang II-induced ROS formation and upregulation of p22(phox) mRNA expression were inhibited by APN and NO. Both compounds failed to inhibit Nox1 and p47(phox) expression.CONCLUSION: Our results suggest that the anti-hypertrophic effects of APN are due, in part, to NO-dependent inhibition of the RhoA/ROCK pathway and ROS formation.

pharmacology & pharmacy
Inhibition of the Na+/Mg2+ exchanger decreases blood pressure and modulates vascular ERK1/2 and p38 MAP kinase phosphorylation in Ang II-induced hypertensive rats

Rhian M. Touyz,Guoying Yao

DOI: https://doi.org/10.1016/S0895-7061(02)02682-1

2002-01-01

American Journal of Hypertension

Abstract:Abnormal regulation of Mg2+ in vascular smooth muscle cells (VSMC) has been implicated to play a role in vascular dysfunction in hypertension. This has been attributed, in part, to increased activation of the Na+/Mg2+ exchanger. We investigated whether inhibition of the Na+/Mg2+ exchanger by quinidine and imipramine influences development of hypertension in Ang II-infused rats. 16 week-old Sprague Dawley rats were randomly divided into 4 groups (6/group): Control (vehicle), Ang II (Ang II, 150 ng/kg/min by osmotic pump), Ang II+quinidine (5 mg/kg/day), Ang II+imipramine (5 mg/kg/day). Rats were treated for 4 weeks. Systolic blood pressure (SBP) and serum cations were measured weekly. Rats were killed by decapitation. Kidneys and mesenteric arteries were collected for determination of MAP kinase expression. [Mg2+]i and [Na+]i were measured in platelets by Mag-fura and SBFI methodology respectively. Phosphorylation of ERK1/2, p38 MAP kinase and JNK was assessed by Western blots using phosphospecific antibodies. SBP increased significantly in the Ang II group (111±1 to 208±6 mmHg). In the quinidine and imipramine groups, SBP increased but the magnitude of increase was significantly less than the Ang II group (quinidine 173±6 mm Hg, imipramine 159±2 mmHg). Serum Mg2+, Ca2+, Na+ and K+ levels were not influenced by treatment. [Mg2+]i was significantly increased and [Na+]i was significantly decreased in the treated groups compared with Ang II group (p<0.01). Phosphorylation of ERK1/2, p38 MAP kinase and JNK was increased 3-5 fold in arteries and kidneys from Ang II rats compared with controls. Quinidine and imipramine significantly reduced (p<0.05) expression of ERK and p38 MAP kinase. Phosphorylation of JNK was not influenced by treatment. Our data demonstrate that quinidine and imipramine attenuate the development of hypertension in Ang II-infused rats. This is associated with increased [Mg2+]i and decreased [Na+]i and reduced phosphorylation of vascular and renal ERK1/2 and p38 MAP kinase. These findings suggest that the Na+/Mg2+ exchanger plays a role in Ang II-dependent hypertension.

Structural differences between blood-platelet tubulin and other mammalian tubulins.

Protective Effects of Auricularia Auriculajudae Polysaccharide on Vascular of Streptozotocin Induced Diabetic Rats

Pentamethylquercetin Attenuates Angiotensin II-induced Abdominal Aortic Aneurysm Formation by Blocking Nuclear Translocation of C/EBPβ at Lys253

Activation AMPK in Hypothalamic Paraventricular Nucleus Improves Renovascular Hypertension Through ERK1/2-NF-κB Pathway

Quercetin Improves Vascular Endothelial Function Through Promotion of Autophagy in Hypertensive Rats

Vascular protein disulfide isomerase A1 mediates endothelial dysfunction induced by angiotensin II in mice

The hydroxamic acid derivative YPX-C-05 alleviates hypertension and vascular dysfunction through the PI3K/Akt/eNOS pathway

Mitochondrial K ATP channel-mediated autophagy contributes to angiotensin II-induced vascular dysfunction in mice

Angiotensin II Decreases Endothelial Nitric Oxide Synthase Phosphorylation via AT1R Nox/ROS/PP2A Pathway

Vascular adenosine monophosphate-activated protein kinase: Enhancer, brake or both?

AMPK attenuates ventricular remodeling and dysfunction following aortic banding in mice via the Sirt3/Oxidative stress pathway

Paeonol improves renal and vascular angiotensin II type 1 receptor function via inhibiting oxidative stress in spontaneously hypertensive rats

Short-chain Acyl-Coa Dehydrogenase is a Potential Target for the Treatment of Vascular Remodelling

Adenosine Kinase Inhibition Enhances Microvascular Dilator Function and Improves Left Ventricle Diastolic Dysfunction

Dual-Functional MN-08 Attenuated Pulmonary Arterial Hypertension Through Vasodilation and Inhibition of Pulmonary Arterial Remodeling

Panax Quinquefolium Saponins enhances angiogenesis in rats with diabetes and myocardial infarction

Astaxanthin Attenuates Hypertensive Vascular Remodeling by Protecting Vascular Smooth Muscle Cells from Oxidative Stress-Induced Mitochondrial Dysfunction

Dipeptidyl peptidase 4 inhibition rescues PKA-eNOS signaling and suppresses aortic hypercontractility in male rats with heart failure

Selective Phosphodiesterase 1 Inhibitor BTTQ Reduces Blood Pressure in Spontaneously Hypertensive and Dahl Salt Sensitive Rats: Role of Peripheral Vasodilation

Adiponectin Attenuates Angiotensin II-Induced Vascular Smooth Muscle Cell Remodeling through Nitric Oxide and the RhoA/ROCK Pathway

Inhibition of the Na+/Mg2+ exchanger decreases blood pressure and modulates vascular ERK1/2 and p38 MAP kinase phosphorylation in Ang II-induced hypertensive rats